PALI PALISADE BIO INC

Palisade Bio to Present at the Virtual Investor Pitch Conference

Palisade Bio to Present at the Virtual Investor Pitch Conference

Live video webcast on Monday, June 17th at 12:00 PM ET

Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will present at the on June 17, 2024 at 12:00 PM ET.

As part of the event, J.D. Finley, Chief Executive Officer of Palisade Bio, will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.

A of the presentation will be available on the page of the section of the Company’s website (). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Palisade Bio 

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

833-475-8247



EN
10/06/2024

Underlying

PALIPALISADE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALISADE BIO INC

 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directo...

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcerative Colitis Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Emil Chuang, MB BS FRACP to its Board of D...

July 9, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-...

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK)  No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment discussing the topline Phase 1a data; Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Pa...

May 27, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Presents Positive Preclinical Data Highlighting Potential...

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade B...

May 6, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Se...

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the being held May 13–15, 2025 in Boston, MA. Detai...

May 1, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/...

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed to date Screening for Phase 1b UC cohort ongoing; On track to report topline data in the first half of 2025 Carlsbad, CA, April 09, 2025 (GLOBE NEWSWIRE) -- P...

April 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch